UKMF Position statement on the use of bendamustine in myeloma

The benefits of bendamustine are increasingly being recognised in the relapsed setting but its optimal use has yet to be defined. Based on a review of current data, the UK Myeloma Forum has produced a position statement providing recommendations for the use of bendamustine as a treatment for myeloma patients in the UK.